查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1983844

失眠治療市場：按藥物類別、劑型、給藥途徑、最終用戶和分銷管道分類的全球市場預測，2026-2032年

Insomnia Drugs Market by Drug Class, Formulation, Route Of Administration, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年失眠治療市場價值 32.4 億美元，預計到 2026 年將成長至 34.3 億美元，複合年成長率為 5.96%，到 ​​2032 年將達到 48.7 億美元。

主要市場統計數據
基準年 2025 32.4億美元
預計年份：2026年 34.3億美元
預測年份 2032 48.7億美元
複合年成長率 (%) 5.96%

簡要概述現代失眠治療趨勢中的治療方法創新、臨床挑戰和商業性因素。

在科學進步、患者期望不斷變化以及監管審查日益嚴格的推動下，失眠治療市場正經歷快速變化。本執行摘要闡述了影響藥物研發、臨床實務、分銷和支付方參與等相關相關人員當前及近期決策的關鍵主題。本概述全面分析了治療方法創新、不斷變化的消費者模式以及支持治療交付的基礎設施，為尋求調整投資以把握新興機會的領導者提供了清晰的切入點。

分析了正在重塑失眠治療藥物的研發和分銷的、模式轉移的臨床進展、支付方的期望以及藥物輸送創新。

失眠治療領域正經歷一場變革，其驅動力包括作用機制的創新、安全性期望的提高以及數位診療路徑的發展。針對Orexin受體的新型化合物正在重塑關於療效和次日起效的臨床討論，促使臨床醫生重新評估處方模式和風險獲益權衡。同時，旨在改善起效時間、持續時間和耐受性的藥物科學進展正在影響產品在門診和住院環境中的定位。

2025 年的關稅調整和貿易趨勢將如何推動失眠藥物供應鏈的重新設計、購買多元化以及對整個價值鏈韌性的投資？

2025年實施的政策和貿易措施，包括關稅調整，為製藥企業和經銷商的全球供應鏈規劃引入了新的變數。這些措施影響了某些進口原料藥、輔料和成品的成本基礎，促使採購團隊重新評估籌資策略和緊急儲備。為此，許多企業正在加速供應商網路多元化，並轉向近岸外包，以降低貿易波動風險。

全面的細分情報揭示了不同治療領域之間的細微差異、製劑和給藥途徑的變化、分銷趨勢以及最終用戶模式，從而幫助制定有針對性的策略。

細分市場分析揭示了影響不同治療領域、劑型、給藥途徑、分銷管道和終端用戶環境的藥物價值和需求的因素存在差異。藥物類別包括抗組織胺、苯二氮平類、褪黑素受體促效劑、非苯二氮平類藥物和Orexin受體拮抗劑。在非苯二氮平類藥物中，具有重要臨床意義的藥物如依佐匹克隆、Zaleplon和Zolpidem在起效時間和半衰期方面表現出不同的特徵，從而影響產品定位。同時，Orexin受體拮抗劑，包括達利德生、倫博雷生和蘇沃雷生，在處方醫師決策中，其療效和耐受性方面存在獨特的爭議。這些差異導致了不同的臨床定位和促銷策略，有些藥物更適合短期症狀管理，而有些則更適合維持治療。

失眠藥物在美洲、歐洲、中東和非洲以及亞太地區面臨不同的區域趨勢和法規，因此需要採取適應性的取得和分銷策略。

區域趨勢持續影響產品策略、監管應對方案和分銷網路設計。在美洲，臨床實踐模式以及公立和私人保險公司之間的互動影響著處方藥的上市，而數位醫療和遠距藥事照護模式的採用則擴大了門診病人範圍並提升了病人參與。美洲市場的進入考量通常著重於展現產品在實際應用功能和安全性方面的差異化優勢，以確保獲得臨床醫生和保險公司的青睞。

我們透過強調治療差異化、數位化合作、生命週期管理和證據產生的競爭和企業策略，確保臨床和商業性優勢。

主要企業之間的競爭特徵是：有針對性的研發投入、建立合作夥伴關係以及專注於生命週期管理，旨在維持臨床意義。每家公司都利用其臨床差異化優勢，例如給藥後第二天即可改善認知功能以及最大限度地降低成癮風險，從而使後期研發和上市產品更受處方醫生和支付方的青睞。製藥開發商與數位醫療供應商之間的策略合作日益普遍，從而能夠提供結合藥物療法和行為干預的解決方案，以解決用藥依從性和長期治療效果問題。

為產業領導者提供實用的策略指南，以協調證據產生、數位整合、彈性供應鏈和個人化商業化，從而建立永續的競爭優勢。

產業領導者應優先考慮整合式方法，將臨床差異化與切實可行的打入市場策略和穩健的供應鏈設計相結合。首先，他們應投資於有針對性的證據生成，以證明藥物的相對療效、患者報告結果和真實世界安全性，從而支持藥物的推廣應用並與支付方展開對話。其次，他們應加強與數位醫療服務提供者的合作，建立整合式照護路徑，以提高患者的用藥依從性並擴大市場覆蓋範圍，尤其是在門診和居家照護領域。此類整合式服務將增強對臨床醫生和支付方的價值提案。

為了確保解釋的準確性，我們採用了嚴謹的多方面調查方法，該方法包括與相關人員的訪談、監管審查、臨床數據的整合以及供應鏈風險評估。

本研究採用跨學科調查方法，結合定性和定量證據來源，旨在闡明失眠治療的現狀。第一階段包括對關鍵相關人員進行結構化訪談，這些利害關係人包括臨床專家、藥物採納決策者、採購經理和分銷合作夥伴，以了解觀點。第二階段利用同儕審查文獻、監管指導文件、臨床試驗註冊資訊和上市公司資訊披露訊息，全面檢驗臨床和監管趨勢。

結論整合了臨床差異化、循證投資、靈活的供應策略和以管道為中心的商業化，以產生永續的影響。

總之，失眠治療領域正受到機制特異性臨床進展、安全性和日常生活功能預期變化以及分銷和醫療服務模式轉型等因素的重塑。將產品開發與差異化臨床特徵相結合、投資於真實世界數據並採用靈活的生產和籌資策略的相關人員，將更有能力應對商業性和監管方面的複雜挑戰。此外，整合數位健康方法並制定針對特定管道的商業化計劃，對於擴大治療覆蓋範圍和提高門診及居家照護環境中的用藥依從性至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：失眠治療市場：依藥物類別分類

  • 抗組織胺藥
  • 苯二氮平類藥物
  • 褪黑素受體促效劑
  • 非苯二氮平類藥物
    • 依佐匹克隆
    • Zaleplon
    • Zolpidem
  • Orexin受體拮抗劑
    • 達利德雷桑
    • 倫博雷桑
    • 斯沃雷桑特

第9章 依劑型分類的失眠治療藥物市場

  • 膠囊
  • 注射藥物
  • 口服懸浮液
  • 舌下片
  • 藥片

第10章：失眠治療市場：依給藥途徑分類

  • 靜脈
  • 口服
  • 舌下
  • 經皮

第11章：失眠治療市場：依最終使用者分類

  • 門診部
  • 診所
  • 居家照護
  • 醫院
    • 私立醫院
    • 公立醫院

第12章：失眠治療市場：依通路分類

  • 藥局
  • 醫院藥房
    • 私立醫院
    • 公立醫院
  • 網路藥房
    • 通用B2C平台
    • 廠商直銷網站
    • 遠距藥事照護服務
  • 零售藥房
    • 連鎖藥局
    • 獨立經營藥房
    • 超級市場內的藥房

第13章：失眠治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 失眠治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 失眠治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國失眠治療市場

第17章：中國失眠治療市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Alembic Pharmaceuticals Limited
  • Astellas Pharma Inc.
  • Aurobindo Pharma Limited
  • Biogen SA
  • Cadila Healthcare Ltd.
  • Dr.Reddy's Laboratories Limited
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Flynn Pharma Limited
  • Glenmark Pharmaceuticals Ltd.
  • Idorsia Pharmaceuticals Ltd.
  • LA Herbal（India）
  • Mallinckrodt Pharmaceuticals
  • Merck & Co., Inc.
  • Minerva Neurosciences, Inc.
  • Neuracle Lifesciences Private Limited
  • Neurim Pharmaceuticals LTD.
  • Orexo AB
  • Pfizer Inc.
  • Purdue Pharma LP
  • Sanofi Group
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Vanda Pharmaceuticals Inc.
  • Wockhardt Limited
Product Code: MRR-F6513A06BE94

The Insomnia Drugs Market was valued at USD 3.24 billion in 2025 and is projected to grow to USD 3.43 billion in 2026, with a CAGR of 5.96%, reaching USD 4.87 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.24 billion
Estimated Year [2026] USD 3.43 billion
Forecast Year [2032] USD 4.87 billion
CAGR (%) 5.96%

A concise contextual introduction framing therapeutic innovation, clinical pressures, and commercial drivers that shape the modern insomnia treatment landscape

The insomnia drugs landscape is undergoing rapid evolution driven by scientific advances, shifting patient expectations, and intensifying regulatory attention. This executive summary introduces the critical themes that shape current and near-term decision-making for stakeholders across pharmaceutical development, clinical practice, distribution, and payer engagement. The overview synthesizes therapeutic innovations, changing consumption patterns, and the infrastructure supporting treatment delivery, offering a clear entry point for leaders seeking to align investments with emerging opportunities.

Importantly, this introduction situates insomnia within a broader healthcare context where comorbid psychiatric and cardiometabolic conditions influence both therapeutic choices and adherence. It highlights how pharmacological differentiation, safety profiles, and convenience of administration increasingly determine clinician preference and patient uptake. The section sets expectations for the subsequent analysis by outlining methodological rigor and the multi-dimensional lens-clinical, regulatory, commercial-used to interpret trends. Readers are invited to proceed with a focus on strategic implications rather than historical volume metrics, as the subsequent sections prioritize actionable insights that support portfolio and market-access decisions.

An analysis of paradigm-shifting clinical advances, payer expectations, and care-delivery innovations that are reshaping insomnia drug development and adoption

The insomnia therapeutics environment is experiencing transformative shifts shaped by innovation in mechanism of action, heightened safety expectations, and digital-enabled care pathways. Novel compounds targeting orexin receptors have recalibrated clinical conversations about efficacy and next-day functioning, prompting clinicians to reassess prescribing patterns and risk-benefit trade-offs. Concurrently, advances in formulation science-aimed at improving onset, duration, and tolerability-are influencing how products are positioned across ambulatory and institutional settings.

Meanwhile, payer scrutiny and regulatory guidance are prompting manufacturers to demonstrate differentiated value through real-world evidence and comparative-effectiveness studies. Digital therapeutics and remote patient monitoring are redefining adjunctive treatment models, enabling stepped-care approaches that combine behavioral and pharmacologic interventions. Additionally, patient-centric packaging and alternative routes of administration are gaining attention as adherence drivers. Collectively, these shifts are altering competitive dynamics, funneling investment into targeted R&D, and encouraging strategic partnerships that accelerate time-to-clinic for next-generation insomnia solutions.

How 2025 tariff adjustments and trade dynamics are prompting supply chain redesigns, procurement diversification, and resilience investments across the insomnia drug value chain

Policy and trade actions, including tariff adjustments implemented in 2025, have introduced new variables into global supply chain planning for pharmaceutical manufacturers and distributors. These measures have affected the cost base for certain imported active pharmaceutical ingredients, excipients, and finished formulations, prompting procurement teams to reassess sourcing strategies and contingency inventories. In response, many organizations have accelerated diversification of supplier networks and increased emphasis on nearshoring to reduce exposure to trade-related volatility.

In addition, the tariff landscape has intensified scrutiny of cost-to-serve calculations across distribution channels. Hospital pharmacies and large retail chains have re-evaluated procurement agreements and inventory management protocols to mitigate margin compression. Meanwhile, manufacturers have revisited manufacturing footprints and supply chain resilience investments, prioritizing flexibility in batch sizes and multi-site qualification. Regulatory compliance considerations and quality assurance requirements continue to shape these adjustments, and companies are increasingly balancing tariff-driven cost pressures with commitments to reliability and therapeutic integrity.

Comprehensive segmentation intelligence revealing therapeutic class nuances, formulation and administration distinctions, distribution dynamics, and end-user patterns that inform targeted strategies

Segmentation analysis reveals differentiated drivers of value and demand across therapeutic class, formulation, route of administration, distribution channel, and end-user settings. The drug class dimension encompasses antihistamines, benzodiazepines, melatonin receptor agonists, non-benzodiazepines, and orexin receptor antagonists; within the non-benzodiazepine category, clinically relevant agents such as eszopiclone, zaleplon, and zolpidem demonstrate varying profiles of onset and half-life that influence positioning, while orexin receptor antagonists including daridorexant, lemborexant, and suvorexant have introduced a distinct efficacy and tolerability conversation into prescriber decision-making. These differences drive divergent clinical narratives and promotional strategies, with some classes remaining more attractive for short-term symptom control and others suited for maintenance therapy considerations.

Formulation choices-ranging from capsules, injectables, oral suspensions, sublingual tablets, to tablets-are shaping product differentiation and patient preference, as ease of use and onset characteristics become competitive levers. Route-of-administration distinctions, including intravenous, oral, sublingual, and transdermal options, further influence hospital versus outpatient utilization and the feasibility of certain therapeutic approaches in primary care or acute settings. Distribution channel segmentation highlights the role of drug stores, hospital pharmacies, online pharmacies, and retail pharmacies in shaping access and adherence; within hospital pharmacies, private and public institutions exhibit differing procurement behaviors, while online pharmacies segment into general B2C platforms, manufacturer direct sites, and telepharmacy services, each presenting unique regulatory and commercial dynamics. Retail pharmacy variations-chain, independent, and supermarket pharmacies-affect promotional reach and point-of-sale engagement strategies. End-user segmentation across ambulatory care centers, clinics, home care, and hospitals underscores divergent care pathways; hospitals themselves differentiate into private and public entities with distinct formulary processes and procurement cycles. By integrating these segmentation lenses, stakeholders can better tailor clinical development, marketing, and distribution tactics to match the nuanced needs of targeted prescribers and patients.

Regional dynamics and regulatory diversity across the Americas, Europe, Middle East & Africa, and Asia-Pacific that require adaptive access and distribution strategies for insomnia therapies

Regional dynamics continue to shape product strategy, regulatory planning, and distribution network design. In the Americas, clinical practice patterns and the interplay between private and public payers influence formulary access, while digital health adoption and telepharmacy models are expanding outpatient reach and patient engagement. Market entry considerations in the Americas often revolve around demonstrating differentiation in real-world functioning and safety to secure favorable positioning with both clinicians and payers.

Within Europe, Middle East & Africa, heterogeneous regulatory frameworks and procurement environments demand adaptive market-access strategies that account for national formularies, public hospital procurement, and private-sector variability. Clinicians across these geographies weigh long-term tolerability and comorbidity profiles heavily in prescribing decisions, and reimbursement pathways can vary significantly between public and private systems. In the Asia-Pacific region, rapid uptake of telemedicine, diverse reimbursement mechanisms, and evolving domestic manufacturing capabilities present both opportunities and complexity. Stakeholders are prioritizing localized evidence generation, regulatory alignment strategies, and partnerships with regional distributors to navigate procurement practices and expedite adoption across public and private healthcare settings. Across all regions, supply chain resilience, local regulatory engagement, and culturally informed patient education remain essential components of successful commercialization.

Competitive and corporate maneuvers emphasizing therapeutic differentiation, digital collaborations, lifecycle management, and evidence generation to secure clinical and commercial advantage

Competitive behavior among leading organizations is characterized by targeted R&D investment, alliance formation, and a focus on lifecycle management aimed at sustaining clinical relevance. Companies are leveraging clinical differentiation, such as improved next-day cognitive profiles and minimized dependency risks, to position late-stage and marketed products more favorably with prescribers and payers. Strategic collaborations between pharmaceutical developers and digital health vendors are becoming more commonplace, enabling combined pharmacologic and behavioral offerings that address adherence and long-term outcomes.

Additionally, some manufacturers are optimizing commercialization by tailoring packaging, patient-support programs, and specialty pharmacy partnerships to specific distribution channels and end-user settings. Mergers, acquisitions, and licensing agreements remain tactical options for expanding portfolios or acquiring differentiated mechanisms of action. Across the competitive landscape, there is increasing emphasis on generating post-approval evidence, including real-world studies and registries, to substantiate value claims and support reimbursement negotiations. Operationally, firms are investing in supply chain flexibility and regulatory expertise to accelerate market entry across multiple geographies while maintaining high standards of quality and safety.

Actionable strategic directives for industry leaders to align evidence generation, digital integration, resilient supply chains, and tailored commercialization for sustainable advantage

Industry leaders should prioritize an integrated approach that aligns clinical differentiation with pragmatic market-access strategies and resilient supply chain design. First, invest in targeted evidence generation that demonstrates comparative effectiveness, patient-reported outcomes, and real-world safety to support formulary inclusion and payer dialogues. Secondly, pursue partnerships with digital health providers to create bundled care pathways that improve adherence and extend market reach, particularly in outpatient and home-care settings. Such combined offerings will enhance value propositions to both clinicians and payers.

Concurrently, optimize manufacturing and procurement by diversifying suppliers and qualifying alternate sites to mitigate exposure to trade and tariff-related disruption. Strengthen engagement with hospital formulary committees through tailored value dossiers and locally relevant real-world data to expedite acceptance in both private and public institutions. Finally, tailor commercialization strategies by aligning formulation and route preferences with distribution channel capabilities and end-user needs, ensuring that messaging addresses both efficacy and daily-life impact. Together, these actions create a coherent plan that balances short-term access priorities with long-term brand sustainability.

A rigorous multi-source research methodology integrating stakeholder interviews, regulatory review, clinical synthesis, and supply chain risk assessment to ensure interpretive rigor

This research employed a multi-disciplinary methodology combining qualitative and quantitative evidence sources to build a robust understanding of the insomnia therapeutic landscape. Primary research involved structured interviews with key stakeholders, including clinical experts, formulary decision-makers, procurement leads, and distribution partners, to capture frontline perspectives on adoption drivers, safety concerns, and operational constraints. Secondary research utilized peer-reviewed literature, regulatory guidance documents, clinical trial registries, and public company disclosures to triangulate clinical and regulatory trends.

Analytical techniques included comparative clinical profiling, segmentation mapping across therapeutic class, formulation, route of administration, distribution channel, and end-user settings, and supply chain risk assessment focused on recent policy and tariff developments. Care was taken to validate insights through cross-referencing multiple independent sources and through iterative expert review. The methodology emphasizes transparency in data sourcing and interpretive rigor, ensuring that conclusions reflect current practice patterns and the prevailing regulatory landscape rather than speculative projections.

A concluding synthesis emphasizing clinical differentiation, evidence investment, flexible supply strategies, and channel-focused commercialization to drive sustainable impact

In conclusion, the insomnia drugs domain is being reshaped by mechanism-specific clinical advances, evolving expectations for safety and daily functioning, and shifts in distribution and care-delivery models. Stakeholders who align product development with differentiated clinical profiles, invest in real-world evidence, and adopt flexible manufacturing and procurement strategies will be better positioned to navigate commercial and regulatory complexity. Additionally, integrating digital health modalities and designing channel-specific commercialization plans will be critical to expanding reach and improving adherence in outpatient and home-care settings.

Moving forward, decision-makers should maintain a dual focus on near-term access imperatives-such as formulary positioning and supply chain resilience-and longer-term investments in evidence that supports differentiated value. By doing so, organizations can create durable competitive advantage while responding responsibly to payer and clinician priorities. The subsequent actionable recommendations and tailored engagement with sales and advisory resources can help translate these strategic directions into operational plans that deliver measurable outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Insomnia Drugs Market, by Drug Class

  • 8.1. Antihistamines
  • 8.2. Benzodiazepines
  • 8.3. Melatonin Receptor Agonists
  • 8.4. Non-Benzodiazepines
    • 8.4.1. Eszopiclone
    • 8.4.2. Zaleplon
    • 8.4.3. Zolpidem
  • 8.5. Orexin Receptor Antagonists
    • 8.5.1. Daridorexant
    • 8.5.2. Lemborexant
    • 8.5.3. Suvorexant

9. Insomnia Drugs Market, by Formulation

  • 9.1. Capsules
  • 9.2. Injectables
  • 9.3. Oral Suspensions
  • 9.4. Sublingual Tablets
  • 9.5. Tablets

10. Insomnia Drugs Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral
  • 10.3. Sublingual
  • 10.4. Transdermal

11. Insomnia Drugs Market, by End User

  • 11.1. Ambulatory Care Centers
  • 11.2. Clinics
  • 11.3. Home Care
  • 11.4. Hospitals
    • 11.4.1. Private Hospitals
    • 11.4.2. Public Hospitals

12. Insomnia Drugs Market, by Distribution Channel

  • 12.1. Drug Stores
  • 12.2. Hospital Pharmacies
    • 12.2.1. Private Hospitals
    • 12.2.2. Public Hospitals
  • 12.3. Online Pharmacies
    • 12.3.1. General B2C Platforms
    • 12.3.2. Manufacturer Direct Sites
    • 12.3.3. Telepharmacy Services
  • 12.4. Retail Pharmacies
    • 12.4.1. Chain Pharmacies
    • 12.4.2. Independent Pharmacies
    • 12.4.3. Supermarket Pharmacies

13. Insomnia Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Insomnia Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Insomnia Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Insomnia Drugs Market

17. China Insomnia Drugs Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Alembic Pharmaceuticals Limited
  • 18.6. Astellas Pharma Inc.
  • 18.7. Aurobindo Pharma Limited
  • 18.8. Biogen SA
  • 18.9. Cadila Healthcare Ltd.
  • 18.10. Dr.Reddy's Laboratories Limited
  • 18.11. Eisai Co., Ltd.
  • 18.12. Eli Lilly and Company
  • 18.13. Flynn Pharma Limited
  • 18.14. Glenmark Pharmaceuticals Ltd.
  • 18.15. Idorsia Pharmaceuticals Ltd.
  • 18.16. LA Herbal (India)
  • 18.17. Mallinckrodt Pharmaceuticals
  • 18.18. Merck & Co., Inc.
  • 18.19. Minerva Neurosciences, Inc.
  • 18.20. Neuracle Lifesciences Private Limited
  • 18.21. Neurim Pharmaceuticals LTD.
  • 18.22. Orexo AB
  • 18.23. Pfizer Inc.
  • 18.24. Purdue Pharma L.P.
  • 18.25. Sanofi Group
  • 18.26. Sun Pharmaceutical Industries Limited
  • 18.27. Takeda Pharmaceutical Company Limited
  • 18.28. Vanda Pharmaceuticals Inc.
  • 18.29. Wockhardt Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL INSOMNIA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL INSOMNIA DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL INSOMNIA DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES INSOMNIA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA INSOMNIA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL INSOMNIA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ANTIHISTAMINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY BENZODIAZEPINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY BENZODIAZEPINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY BENZODIAZEPINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY MELATONIN RECEPTOR AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ESZOPICLONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ESZOPICLONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ESZOPICLONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ZALEPLON, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ZALEPLON, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ZALEPLON, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ZOLPIDEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ZOLPIDEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ZOLPIDEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DARIDOREXANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DARIDOREXANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DARIDOREXANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY LEMBOREXANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY LEMBOREXANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY LEMBOREXANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUVOREXANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUVOREXANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUVOREXANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INJECTABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INJECTABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ORAL SUSPENSIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ORAL SUSPENSIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ORAL SUSPENSIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUBLINGUAL TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUBLINGUAL TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUBLINGUAL TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUBLINGUAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUBLINGUAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUBLINGUAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DRUG STORES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY DRUG STORES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY GENERAL B2C PLATFORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY GENERAL B2C PLATFORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY GENERAL B2C PLATFORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY MANUFACTURER DIRECT SITES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY MANUFACTURER DIRECT SITES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY MANUFACTURER DIRECT SITES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TELEPHARMACY SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TELEPHARMACY SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY TELEPHARMACY SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUPERMARKET PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUPERMARKET PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY SUPERMARKET PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 133. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 134. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA INSOMNIA DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA INSOMNIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE INSOMNIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST INSOMNIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 198. MIDDLE EAST INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA INSOMNIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 211. AFRICA INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC INSOMNIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN INSOMNIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 237. GCC INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. GCC INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 239. GCC INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 240. GCC INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 241. GCC INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 242. GCC INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 243. GCC INSOMNIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. GCC INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 245. GCC INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 246. GCC INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 247. GCC INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 248. GCC INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION INSOMNIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS INSOMNIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 273. G7 INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. G7 INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 275. G7 INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 276. G7 INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 277. G7 INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 278. G7 INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 279. G7 INSOMNIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 280. G7 INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 281. G7 INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 282. G7 INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 283. G7 INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 284. G7 INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 285. NATO INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 286. NATO INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 287. NATO INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 288. NATO INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 289. NATO INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 290. NATO INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 291. NATO INSOMNIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 292. NATO INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 293. NATO INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 294. NATO INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 295. NATO INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 296. NATO INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 297. GLOBAL INSOMNIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES INSOMNIA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED STATES INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED STATES INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED STATES INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES INSOMNIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED STATES INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED STATES INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED STATES INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 308. UNITED STATES INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 309. UNITED STATES INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 310. CHINA INSOMNIA DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 311. CHINA INSOMNIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 312. CHINA INSOMNIA DRUGS MARKET SIZE, BY NON-BENZODIAZEPINES, 2018-2032 (USD MILLION)
  • TABLE 313. CHINA INSOMNIA DRUGS MARKET SIZE, BY OREXIN RECEPTOR ANTAGONISTS, 2018-2032 (USD MILLION)
  • TABLE 314. CHINA INSOMNIA DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 315. CHINA INSOMNIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 316. CHINA INSOMNIA DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 317. CHINA INSOMNIA DRUGS MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 318. CHINA INSOMNIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 319. CHINA INSOMNIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 320. CHINA INSOMNIA DRUGS MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 321. CHINA INSOMNIA DRUGS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)